» Articles » PMID: 25866592

Epidemiology and Management of Antiretroviral-associated Cardiovascular Disease

Overview
Journal Open AIDS J
Publisher Bentham Open
Date 2015 Apr 14
PMID 25866592
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Risk and manifestations of cardiovascular disease (CVD) in patients infected with human immunodeficiency virus (HIV) will continue to evolve as improved treatments and life expectancy of these patients increases. Although initiation of antiretroviral (ARV) therapy has been shown to reduce this risk, some ARV medications may induce metabolic abnormalities, further compounding the risk of CVD. In this patient population, both pharmacologic and nonpharmacologic strategies should be employed to treat and reduce further risk of CVD. This review summarizes epidemiology data of the risk factors and development of CVD in HIV and provides recommendations to manage CVD in HIV-infected patients.

Citing Articles

Evolving mechanisms and presentations of cardiovascular disease in people with HIV: implications for management.

Nazari I, Feinstein M Clin Microbiol Rev. 2024; 37(1):e0009822.

PMID: 38299802 PMC: 10938901. DOI: 10.1128/cmr.00098-22.


HIV-Positive Patient With Non-Percutaneous Coronary Intervention (PCI)-Amenable Left Coronary Artery Aneurysms Presenting With ST-Elevation Myocardial Infarction (STEMI).

Khan R, Najam U, Cheikh Debs D, Myers J, Graham S Cureus. 2023; 15(3):e36703.

PMID: 37113349 PMC: 10128888. DOI: 10.7759/cureus.36703.


Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study.

Antinori A, Rusconi S, Gianotti N, Bini T, Mancusi D, Termini R Drug Des Devel Ther. 2019; 13:1667-1685.

PMID: 31190745 PMC: 6526181. DOI: 10.2147/DDDT.S180981.


The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV.

Ahn M, Jiamsakul A, Khusuwan S, Khol V, Pham T, Chaiwarith R J Int AIDS Soc. 2019; 22(2):e25228.

PMID: 30803162 PMC: 6389354. DOI: 10.1002/jia2.25228.


Mild renal impairment is associated with calcified plaque parameters assessed by computed tomography angiography in people living with HIV.

Cheru L, Fitch K, Saylor C, Lu M, Hoffmann U, Lo J AIDS. 2018; 33(2):219-227.

PMID: 30325774 PMC: 6298826. DOI: 10.1097/QAD.0000000000002055.


References
1.
Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A . HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2007; 199(1):79-86. PMC: 2518204. DOI: 10.1016/j.atherosclerosis.2007.10.018. View

2.
Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S . Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA. 2004; 292(2):210-8. DOI: 10.1001/jama.292.2.210. View

3.
Carr A, Miller J, Law M, Cooper D . A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000; 14(3):F25-32. DOI: 10.1097/00002030-200002180-00001. View

4.
Sherer R . HIV, HAART, and hyperlipidemia: balancing the effects. J Acquir Immune Defic Syndr. 2004; 34 Suppl 2:S123-9. DOI: 10.1097/00126334-200310012-00005. View

5.
Milazzo L, Menzaghi B, Corvasce S, Bonfanti P, Rusconi S, Ridolfo A . Safety of statin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2007; 46(2):258-60. DOI: 10.1097/QAI.0b013e3181142e43. View